Hospital

Pafolacianine enables fluorescence-guided lung cancer surgery, with inpatient pharmacy integral to safe procurement, preparation, and interdisciplinary coordination.

From isotope decay to patient access, radiopharmaceuticals present unique challenges for oncology pharmacists.

A new machine learning version of the Martin-Hopkins equation matches the original's accuracy while making implementation easier for laboratories.

Suzetrigine prescriptions approached 1 million in the first half of 2026 as reimbursed access expanded, signaling growing adoption of nonopioid acute pain treatment.

A cone snail venom–derived peptide selectively inhibited the norepinephrine transporter and reduced inflammatory pain behavior without sedation in mice.

Darren Evans, PharmD, discusses what pharmacy leaders at other rural or regional health systems should consider before building a similar model.

AI-enabled scheduling, multidisciplinary coordination, and workflow redesign can help cancer centers manage growing patient volumes without compromising safety or workforce well-being.

The FDA approved once-daily centanafadine (Simtriyo), the first norepinephrine, dopamine, and serotonin reuptake inhibitor for ADHD in adults and children aged 6 years and older weighing at least 20 kg.

Predictive scheduling can improve staffing, pharmacy preparation, infusion capacity, and the overall patient experience.

July 2026 brought major hematology advances in gene therapy, transplantation, targeted treatments, and bleeding disorder care, alongside notable clinical trial setbacks.

In an interview with Pharmacy Times, Ming-Hei Tai, PharmD, BCOP, discusses emerging bladder-preserving therapies for NMIBC, the limitations of single-arm trial data, the continued role of BCG, and the clinical and operational factors that should guide treatment selection.

Morning appointments don't appear to offer any immunologic edge over afternoon ones, new data from more than 15 million patients suggest.

A 19-protein plasma panel predicted whether and when presymptomatic carriers of ALS-associated pathogenic variants would develop clinically manifest disease more accurately than neurofilament light chain alone.

Advance verification, multidisciplinary coordination, and AI-enabled forecasting can help infusion centers adjust schedules and treatment plans during chemotherapy shortages.

Angie Maynard, PharmD, MS, BCOP, discusses RCC immunotherapy guidelines, treatment selection, toxicity management, and pharmacists’ clinical role.

Modern pharmacists increasingly serve as translators, helping patients navigate health care complexity, reduce confusion, and improve understanding through meaningful conversations.

Agitation associated with Alzheimer disease carries clinical challenges, and Auvelity's approval can reshape treatment selection, safety monitoring, and the pharmacist's role.

Erica Marini, PharmD, MS, BCPS; and Millad Sobhanian, PharmD, BCPS, unpack Auvelity's approval, efficacy data, and safety profile for treating agitation in Alzheimer disease.

Hackensack Meridian Health uses a multifaceted approach to diversion auditing and DEA/state reporting requirements, and is beginning to integrate artificial Intelligence (AI) to shift surveillance from a reactive to a proactive process.

Subcutaneous isatuximab could compete with daratumumab in multiple myeloma by combining a hands-free, on-body delivery system with potential advantages in workflow, patient experience, and mechanisms of action.

Updated phase 1/2 findings showed that emavusertib-based therapy produced responses in both BTK inhibitor–naive and –treated patients with relapsed or refractory primary central nervous system (CNS) lymphoma.

Seth Martin, MD, MHS, discusses a simplified machine-learning equation that helps labs deliver more accurate LDL-C results at no cost.

Deepika Nayyar outlines how HMH built a multidisciplinary drug diversion prevention program and shares the core elements any institution needs to detect and respond to diversion effectively.

Pharmacists can use motivational interviewing as a technique to encourage influenza vaccination.

Ravulizumab-cwvz did not significantly improve 26-week event-free survival in adults and adolescents with HSCT-associated thrombotic microangiopathy.

The review combines mechanistic and real-world evidence to guide health care professionals through different scenarios in the MS treatment space.

Brendon Neuen, PhD, MBBS, discusses findings from the FIND-CKD study showing that finerenone benefits patients with nondiabetic chronic kidney disease (CKD) and glomerular disease, as well as those receiving combination SGLT2i therapy.

Adding consolidative thoracic radiotherapy to atezolizumab maintenance increased serious and fatal adverse events without improving survival in patients with ES-SCLC.